The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for abrdn Asia Ltd
JBCHEPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
abrdn Asia Ltd (formerly Aberdeen Group), a foreign institutional investor group, has filed a disclosure under SEBI's Takeover Code Regulation 29(1) for JB Chemicals & Pharmaceuticals. The disclosure shows abrdn's shareholding in the company has decreased from 7,328,508 shares (5.804%) to 6,335,544 shares (5.015%), a reduction of about 992,964 shares or 0.789 percentage points. The change in holding occurred on 20 March 2025 and the intimation was filed on 27 March 2025. The shares are held across multiple abrdn-managed funds, including The India Fund, Indian Equity Fund, Asian Smaller Companies Fund, abrdn Asia Focus plc, abrdn New India Investment Trust plc, and several Emerging Markets funds, held through various global custodians such as State Street Bank, Citibank, and BNP Paribas.
abrdn's stake remains just above the 5% substantial shareholder threshold, keeping it within the scope of SEBI's takeover code disclosure rules. A reduction of nearly 1 percentage point by a major FII may be seen as a mild negative signal by some investors, though abrdn continues to remain a significant institutional holder in JB Chemicals.